232 related articles for article (PubMed ID: 38066938)
1. Management of limited-stage Hodgkin lymphoma.
Al-Juhaishi T; Ahmed S
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):500-509. PubMed ID: 38066938
[TBL] [Abstract][Full Text] [Related]
2. Controversies in the management of early-stage Hodgkin lymphoma.
Blum KA
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):234-239. PubMed ID: 34889367
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies in the Treatment of Hodgkin Lymphoma.
Andrade-Gonzalez X; Ansell SM
Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
Abramson JS; Arnason JE; LaCasce AS; Redd R; Barnes JA; Sokol L; Joyce R; Avigan D; Neuberg D; Takvorian RW; Hochberg EP; Bello CM
Blood; 2019 Aug; 134(7):606-613. PubMed ID: 31186274
[TBL] [Abstract][Full Text] [Related]
5. Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma.
Allen PB; Winter JN
Curr Oncol Rep; 2019 Mar; 21(5):39. PubMed ID: 30919161
[TBL] [Abstract][Full Text] [Related]
6. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
7. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
8. Hodgkin lymphoma: Focus on evolving treatment paradigms.
Roswarski JL; Longo DL
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101510. PubMed ID: 38092470
[TBL] [Abstract][Full Text] [Related]
9. Advanced stages of classical Hodgkin lymphoma - first-line treatment options.
Mociková H
Klin Onkol; 2021; 34(6):450-454. PubMed ID: 34911330
[TBL] [Abstract][Full Text] [Related]
10. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
Metzger ML; Link MP; Billett AL; Flerlage J; Lucas JT; Mandrell BN; Ehrhardt MJ; Bhakta N; Yock TI; Friedmann AM; de Alarcon P; Luna-Fineman S; Larsen E; Kaste SC; Shulkin B; Lu Z; Li C; Hiniker SM; Donaldson SS; Hudson MM; Krasin MJ
J Clin Oncol; 2021 Jul; 39(20):2276-2283. PubMed ID: 33826362
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.
Choi Y; Diefenbach CS
Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732
[No Abstract] [Full Text] [Related]
12. SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
Watkins MP; Fanale MA; Bartlett NL
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):81-90. PubMed ID: 29366607
[TBL] [Abstract][Full Text] [Related]
13. [Classic Hodgkin lymphoma].
Makita S
Rinsho Ketsueki; 2023; 64(6):504-513. PubMed ID: 37407475
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
Kumar A; Casulo C; Advani RH; Budde E; Barr PM; Batlevi CL; Caron P; Constine LS; Dandapani SV; Drill E; Drullinsky P; Friedberg JW; Grieve C; Hamilton A; Hamlin PA; Hoppe RT; Horwitz SM; Joseph A; Khan N; Laraque L; Matasar MJ; Moskowitz AJ; Noy A; Palomba ML; Schöder H; Straus DJ; Vemuri S; Yang J; Younes A; Zelenetz AD; Yahalom J; Moskowitz CH
J Clin Oncol; 2021 Jul; 39(20):2257-2265. PubMed ID: 33909449
[TBL] [Abstract][Full Text] [Related]
15. Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement.
Mociková H; Malikova H; Holesta M; Elturki A; Campr V; Kozak T
Am J Case Rep; 2020 Mar; 21():e921657. PubMed ID: 32170052
[TBL] [Abstract][Full Text] [Related]
16. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
Vassilakopoulos TP; Liaskas A; Pereyra P; Panayiotidis P; Angelopoulou MK; Gallamini A
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685994
[TBL] [Abstract][Full Text] [Related]
17. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD012643. PubMed ID: 31525824
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2022 Nov; 97(11):1478-1488. PubMed ID: 36215668
[TBL] [Abstract][Full Text] [Related]
19. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
Castellino SM; Pei Q; Parsons SK; Hodgson D; McCarten K; Horton T; Cho S; Wu Y; Punnett A; Dave H; Henderson TO; Hoppe BS; Charpentier AM; Keller FG; Kelly KM
N Engl J Med; 2022 Nov; 387(18):1649-1660. PubMed ID: 36322844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
